Sugi Predict

Sugi Predict / Compounds / SCHEMBL18151194

SCHEMBL18151194

SCHEMBL18151194

O=C(NC1CC1)c1ccc(-c2ccc3nc4n(c3c2)C(c2ccccc2)CC4)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ SMYD3 Q9H7B4 2/20 0.46
▸ CYP46A1 Q9Y6A2 1/20 0.42
▸ ACSS2 Q9NR19 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TTK P33981 1/20 0.41
▸ DRD2 P14416 3/20 0.41
▸ DRD4 P21917 3/20 0.41
▸ ATR Q13535 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ BACE1 P56817 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ RIPK1 Q13546 1/20 0.40
▸ MKNK1 Q9BUB5 1/20 0.40
▸ MKNK2 Q9HBH9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18151113 0.89 RIPK1 (0.49) NPC1RAB9ASMN1; SMN2ACSS2RIPK1
SCHEMBL18151304 0.86 PDE2A (0.46) ACSS2HPGDALDH1A1RIPK1
SCHEMBL18151335 0.86 BRAF (0.49) NPC1RAB9AKMT2AACSS2HPGD
SCHEMBL18151730 0.85 CHEK2 (0.41) RIPK1MKNK1MKNK2
SCHEMBL18151263 0.83 RIPK1 (0.49) MEN1KMT2AACSS2HPGDALDH1A1
SCHEMBL18152062 0.81 RIPK1 (0.47) ACSS2RIPK1
SCHEMBL18151393 0.80 HPGD (0.53) MEN1NPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL18150978 0.80 RIPK1 (0.41) HPGDALDH1A1RIPK1
SCHEMBL18151508 0.77 MAP4K4 (0.45) ACSS2
SCHEMBL18151649 0.77 RIPK1 (0.47) SMN1; SMN2ACSS2RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP claimed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US claimed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO claimed
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins AVILAR THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 — — US disclosed
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-08-28 — — US disclosed
EP-4493221-A2 TARGETED BIFUNCTIONAL DEGRADERS Yale University (US) 2025-01-22 — — EP disclosed
WO-2024182772-A2 MANNOSE 6-PHOSPHATE RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
WO-2024098039-A2 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2023178199-A2 TARGETED BIFUNCTIONAL DEGRADERS YALE UNIVERSITY (US) 2023-09-21 — — WO disclosed
US-20230087994-A1 TARGETED BIFUNCTIONAL DEGRADERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-03-23 — — US disclosed
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-06-28 — — US disclosed
EP-3288939-A1 TRICYCLIC MODULATORS OF TNF SIGNALING AbbVie Inc. (US) 2018-03-07 — — EP disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-9856253-B2 Tricyclic modulators of TNF signaling ABBVIE, INC. (US) 2018-01-02 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. 2016-10-20 — — US disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed
WO-2016168641-A1 TRICYCLIC MODULATORS OF TNF SIGNALING ABBVIE INC. (US) 2016-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250269043-A1 TARGETED BIFUNCTIONAL DEGRADERS SMURF2, SMURF1, MDM2 MEN1 1704/4885NPC1 3958/4885RAB9A 2215/4885
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B MEN1 4703/4885NPC1 746/4885RAB9A 1949/4885
US-20230087994-A1 TARGETED BIFUNCTIONAL DEGRADERS SMURF2, SMURF1, SSB MEN1 1509/4885NPC1 3894/4885RAB9A 2233/4885
US-20160304517-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 MEN1 2587/4885NPC1 2264/4885RAB9A 3283/4885
US-20260131007-A1 Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins IGF2R, M6PR, MSR1 MEN1 3214/4885NPC1 1750/4885RAB9A 1378/4885
US-20180179198-A1 TRICYCLIC MODULATORS OF TNF SIGNALING TNF, TNFRSF1A, CD40 MEN1 2587/4885NPC1 2264/4885RAB9A 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.